Article Text

Download PDFPDF
EU News
  1. Richard Price
  1. Correspondence to Richard Price, Department of Policy and Advocacy, European Association of Hospital Pharmacy, 3 Rue Abbe Cuypers, Brussels 1040, Belgium; richard.price{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commission, Council and European Parliament agree content of new European Union Trials regulation

At the end of December 2013, the European Commission, Council of Ministers (representing European Union (EU) national governments), and the European Parliament reached an agreement as to the terms of a new EU clinical trials regulation, which will replace the current, and much criticised, 2001 Directive on trial authorisation procedures within the EU.

The new regulation is aimed primarily at dealing with criticisms that the 2001 Directive created a more burdensome and bureaucratic environment for conducting clinical trials, with evidence of a reduced number of trials taking place in Europe as a result. The new regulation will therefore:

  • Reduce the potential for member states to interpret requirements differently, leading to duplication in assessment and authorisation procedures for multinational trials.

  • Create a single EU portal for trial assessment and authorisation, under the authority of the European Medicines Agency (EMA).

  • Introduce more proportionate forms of regulatory requirement where a trial is considered …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.